Get the Stockscreener App
112.45
2.53%
2.77
After Hours:
112.98
0.53
+0.47%
Halozyme Therapeutics Inc stock is traded at $112.45, with a volume of 10.35M.
It is up +2.53% in the last 24 hours and up +7.21% over the past month.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$109.68
Open:
$109.72
24h Volume:
10.35M
Relative Volume:
5.39
Market Cap:
$12.76B
Revenue:
$1.51B
Net Income/Loss:
$348.84M
P/E Ratio:
40.44
EPS:
2.7805
Net Cash Flow:
$667.65M
1W Performance:
+4.90%
1M Performance:
+7.21%
6M Performance:
+76.67%
1Y Performance:
+46.65%
1-Day Range:
$109.38
$112.66
1-Week Range:
$105.50
$112.66
52-Week Range:
$61.23
$112.66
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Name
Halozyme Therapeutics Inc
Sector
Industry
Phone
(858) 794-8889
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
112.45 | 12.17B | 1.51B | 348.84M | 667.65M | 2.7805 |
VRTX
Vertex Pharmaceuticals Inc
|
508.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.85 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.32 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.04 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.95 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-25 | Downgrade | Goldman | Neutral → Sell |
| Oct-14-25 | Upgrade | Leerink Partners | Underperform → Market Perform |
| Aug-06-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-10-25 | Resumed | Goldman | Neutral |
| May-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Downgrade | Leerink Partners | Market Perform → Underperform |
| Oct-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-19-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-07-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-29-24 | Initiated | TD Cowen | Outperform |
| Jul-24-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-24-23 | Initiated | H.C. Wainwright | Buy |
| May-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Berenberg | Buy |
| Mar-16-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Dec-21-22 | Resumed | Morgan Stanley | Overweight |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Initiated | Evercore ISI | Outperform |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-21-21 | Reiterated | The Benchmark Company | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jul-01-20 | Initiated | The Benchmark Company | Buy |
| Feb-05-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Buy |
| Nov-05-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-19-18 | Resumed | Piper Jaffray | Neutral |
| May-11-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Oct-16-17 | Reiterated | Piper Jaffray | Overweight |
| Jan-06-17 | Downgrade | Citigroup | Buy → Neutral |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Nov-18-15 | Initiated | Citigroup | Buy |
| Sep-22-15 | Initiated | Barclays | Overweight |
| Jun-22-15 | Reiterated | JP Morgan | Overweight |
| Mar-03-15 | Reiterated | UBS | Buy |
| Feb-18-15 | Reiterated | MLV & Co | Buy |
| Jan-08-15 | Reiterated | MLV & Co | Buy |
View All
Halozyme Therapeutics Inc Stock (HALO) Latest News
Halozyme president and CEO Helen Torley sells $6.4 million in stock By Investing.com - Investing.com South Africa
Halozyme president and CEO Helen Torley sells $6.4 million in stock - Investing.com Australia
Halozyme (NASDAQ: HALO) CEO exercises options, sells 60,000 shares - Stock Titan
Record Revenue Growth Boosts Halozyme Shares - FXEmpire
Why (HALO) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026 - GlobeNewswire Inc.
Alteogen Licenses ALT-B4 to Novartis in Deal Worth Up to $3.2 Billion, Reaffirming Value of SC Formulation Platform - finance.biggo.com
Halozyme at Wells Fargo healthcare conference: subQ push gains steam By Investing.com - Investing.com UK
Transcript : Halozyme Therapeutics, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 03 - marketscreener.com
Halozyme Therapeutics (NASDAQ:HALO) Screens Well on High Growth Momentum and Breakout Setup - ChartMill
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Biotech Powerhouse with a Revenue Growth of 47.70% - DirectorsTalk Interviews
Biotech Stocks At 52-Week HighsATTO, HALO, IKT, TVTX, ATRC - RTTNews
Halozyme Therapeutics | SCHEDULE 13G: Others - Moomoo
Halozyme Therapeutics stock hits all-time high at 109.69 USD By Investing.com - Investing.com Nigeria
Halozyme (NASDAQ: HALO) awards board member new RSUs and options vesting at 2027 meeting - Stock Titan
Halozyme Therapeutics stock hits all-time high at 109.69 USD - Investing.com
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $115 - Moomoo
Halozyme Investor Conferences Put ENHANZE and Expanded Drug Delivery Portfolio in Focus - Yahoo Finance
Halozyme to Participate at Upcoming Investor Conferences - marketscreener.com
Three Halozyme executive talks will be webcast in September - stocktitan.net
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Halozyme: The Market May Be Underpricing The Second Growth Wave (NASDAQ:HALO) - Seeking Alpha
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Robust Growth Trajectory in the Biotech Sector - DirectorsTalk Interviews
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice - Eastern Progress
Halozyme Therapeutics (HALO) Stock Trades At A Premium To Fair Value - Yahoo Finance
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen - Yahoo Finance
Halozyme Therapeutics stock hits all-time high at 109.59 USD By Investing.com - Investing.com Nigeria
Halozyme Therapeutics stock hits all-time high at 109.59 USD - investing.com
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Strong Revenue Growth and Robust Pipeline Drive Investor Interest - DirectorsTalk Interviews
Halozyme (HALO) Stock Could Be Fully Priced On The Board Appointment - Sahm
New Halozyme (NASDAQ: HALO) director logs zero stock in first ownership filing - Stock Titan
HALO Stock Rises 36% in a Month: Here's What You Should Know - TradingView
Great Lakes Advisors LLC Purchases Shares of 36,039 Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (HALO) Adds A New Director, Is It 21% Overvalued? - Sahm
Aurora Investment Counsel Takes Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme CEO Helen Torley sells $6.28m in company shares By Investing.com - Investing.com Australia
Halozyme CEO Helen Torley sells $6.28m in company shares - Investing.com
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock - MarketBeat
Halozyme (NASDAQ: HALO) CEO sells tens of thousands of shares - Stock Titan
Halozyme (HALO) Levels: Moves 2.60% Up to $107.62 in the Latest Reading; Range View: Price Remains Between $102.24 Support and $113.00 Resistance for the Current SessionInsider Buying Alerts - Vinanet
Halozyme Appoints Dannielle Appelhans to Board of Directors - The Globe and Mail
Foster & Motley Inc. Invests $2 Million in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Diversify Advisory Services LLC Invests $2.77 Million in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics Appoints Dannielle Appelhans to Board of Directors - Kalkine Media
Halozyme Therapeutics (NASDAQ:HALO): What Is Driving the Rally? - Kalkine Media
Halozyme adds Dannielle Appelhans to board of directors - Investing.com
Halozyme adds Dannielle Appelhans to board of directors By Investing.com - Investing.com Australia
Halozyme Therapeutics stock hits all-time high of 104.86 USD By Investing.com - Investing.com Australia
Halozyme Appoints Dannielle Appelhans to its Board of Directors - PR Newswire
Halozyme Therapeutics (NASDAQ:HALO) Reaches New 52-Week HighWhat's Next? - MarketBeat
Halozyme Therapeutics Inc Stock (HALO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):